The potential role of targeted therapies in the management of neuroendocrine tumours
| Journal | Volume 72 - 2009 |
| Issue | Fasc.1 - Case series |
| Author(s) | G. Verset, I. Borbath, T. Delaunoit, P. Demetter, G. Demolin, A. Hendlisz, P. Pattyn, S. Pauwels, M. Peeters, G. Roeyen, E. Van Cutsem, C. Verslype, J.L. Van Laethem |
| Full article |
 VIEW FREE PDF |
| (1) Department Gastrointestinal Oncology Unit, Erasme University Hospital, Anderlecht ; (2) Department of Gastroenterology, Cliniques Universitaires Saint-Luc, Brussels ; (3) Department of Gastroenterology and Medical Oncology, Jolimont Hospital, Haine-St-Paul ; (4) Department of Pathology, Erasme University Hospital, Anderlecht ; (5) Department of Gastroenterology and Oncology, C.H.C. St. Joseph, Liège ; (6) Medical Oncology Clinic, Institut Jules Bordet, Brussels ; (7) Department of Gastrointestinal Surgery, University Hospital Gent, Gent ; (8) Department of Nuclear Medicine, Cliniques Universitaires Saint-Luc, Brussels ; (9) Department of Gastroenterology, University Hospital Gent, Gent ; (10) Department of Hepatobiliary, Endocrine and Transplantation Surgery, University Hospital Antwerp, Edegem ; (11) Department of Digestive Oncology, University Hospital Gasthuisberg, Leuven ; (12) Department of Internal Medicine and Gastroenterology, St. Lucas Hospital, Brugge ; (13) Department of Hepatology and Digestive Oncology, University Hospital Gasthuisberg, Leuven. |
|
The management of gastro-entero-pancreatic neuroendocrine tumours is evolving thanks to new TNM-classification, diagnostic and staging procedures and new therapeutic options. Targeting new pathways, mostly angiogenesis, development of novel agents is under way and opens new perspectives in controlling the evolution of these tumours and possibly changing their management. In parallel, new functional imaging techniques and biomolecular markers will be developed to provide adequate tools for the assess- ment of tumor response according to therapeutic intervention on angiogenesis, proliferation and apoptosis. This paper reviews the potential role of new investigational targeted agents which will likely become the backbone of future therapy of neuroendocrine tumors. (Acta gastroenterol. belg., 2009, 72, 59-62). |
|
© Acta Gastro-Enterologica Belgica. PMID 19402374 |
